Hoekstra O S, van Lingen A, Ossenkoppele G J, Golding R, Teule G J
Department of Nuclear Medicine, Free University Hospital, Amsterdam, The Netherlands.
Eur J Nucl Med. 1993 Dec;20(12):1214-7. doi: 10.1007/BF00171020.
Metabolic response monitoring early during chemotherapy may have a major impact on clinical management of patients with malignant lymphoma. In two patients with non-Hodgkin's lymphoma fluorine-18 fluorodeoxyglucose (18FDG) single-photon emission tomography (SPET) studies were performed during the first two chemotherapeutic cycles. Persisting uptake predicted treatment failure whereas a sharp reduction of 18FDG uptake was demonstrated in the case of a responsive tumour. Qualitative analysis of conventional 18FDG imaging may thus serve to identify patients with a non-responding tumour. The potential of this technique in the determination of the initial response remains to be established. Imaging with 18FDG and SPET appears promising as a more easily available methodology than 18FDG positron emission tomography.
化疗早期的代谢反应监测可能对恶性淋巴瘤患者的临床管理产生重大影响。在两名非霍奇金淋巴瘤患者中，在头两个化疗周期内进行了氟-18氟脱氧葡萄糖（18FDG）单光子发射断层扫描（SPET）研究。持续摄取预示治疗失败，而在反应性肿瘤病例中显示18FDG摄取急剧减少。因此，常规18FDG成像的定性分析可用于识别无反应肿瘤的患者。该技术在确定初始反应方面的潜力仍有待确定。与18FDG正电子发射断层扫描相比，18FDG和SPET成像作为一种更容易获得的方法似乎很有前景。
